EXODIAB: Excellence of Diabetes Research in Sweden
21 – 30 of 4146
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Associations of clinical, psychological, and sociodemographic characteristics and ecological momentary assessment completion in the 10-week Hypo-METRICS study : Hypoglycaemia MEasurements ThResholds and ImpaCtS
2024) In Diabetic Medicine(
- Contribution to journal › Article
-
Mark
A Federated Database for Obesity Research : An IMI-SOPHIA Study
(
- Contribution to journal › Article
-
Mark
Expression of Stress-Induced Genes in Bronchoalveolar Lavage Cells and Lung Fibroblasts from Healthy and COPD Subjects
(
- Contribution to journal › Article
-
Mark
RFX6 haploinsufficiency predisposes to diabetes through impaired beta cell function
2024) In Diabetologia(
- Contribution to journal › Article
-
Mark
Intracellular complement and immunometabolism : The advantages of compartmentalization
2024) In European Journal of Immunology(
- Contribution to journal › Scientific review
-
Mark
Lifestyle and cardiovascular risk factors in a Swedish primary care population with self-reported psychiatric symptoms
(
- Contribution to journal › Article
-
Mark
Oral Insulin Delay of Stage 3 Type 1 Diabetes Revisited in HLA DR4-DQ8 Participants in the TrialNet Oral Insulin Prevention Trial (TN07)
(
- Contribution to journal › Article
-
Mark
Self-Report Tool for Identification of Individuals With Coronary Atherosclerosis : The Swedish CardioPulmonary BioImage Study
(
- Contribution to journal › Article
-
Mark
Cardioneuroablation for treatment of atrioventricular block : to cure the patient or the electrocardiogram?
2024) In Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 26(7). p.1-3(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients
(
- Contribution to journal › Article